Voloridge Investment Management
TXG icon

Voloridge Investment Management’s 10x Genomics TXG Stock Holding History

Voloridge Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-497,157
Closed -$10.6M – 1088
2026
Q1 		$10.6M Sell
497,157
-731,546
-60% -$14.6M 0.04% 496
2025
Q4 		$20M Sell
1,228,703
-92,553
-7% -$1.4M 0.07% 363
2025
Q3 		$15.4M Sell
1,321,256
-205,636
-13% -$2.68M 0.05% 423
2025
Q2 		$17.7M Sell
1,526,892
-96,783
-6% -$882K 0.07% 366
2025
Q1 		$14.2M Buy
1,623,675
+37,710
+2% +$475K 0.05% 453
2024
Q4 		$22.8M Buy
1,585,965
+171,161
+12% +$2.7M 0.08% 315
2024
Q3 		$31.9M Sell
1,414,804
-25,238
-2% -$522K 0.12% 266
2024
Q2 		$28M Buy
1,440,042
+538,297
+60% +$14.1M 0.1% 276
2024
Q1 		$33.8M Buy
901,745
+365,024
+68% +$16M 0.12% 229
2023
Q4 		$30M Sell
536,721
-19,261
-3% -$838K 0.12% 225
2023
Q3 		$22.9M Buy
555,982
+224,942
+68% +$11.7M 0.11% 250
2023
Q2 		$18.5M Buy
331,040
+4,332
+1% +$234K 0.09% 307
2023
Q1 		$18.2M Sell
326,708
-205,494
-39% -$9.6M 0.09% 311
2022
Q4 		$19.4M Sell
532,202
-227,129
-30% -$7.43M 0.11% 273
2022
Q3 		$21.6M Sell
759,331
-23,731
-3% -$904K 0.12% 244
2022
Q2 		$35.4M Buy
783,062
+418,718
+115% +$21.7M 0.18% 157
2022
Q1 		$27.7M Buy
364,344
+351,300
+2,693% +$30.7M 0.16% 189
2021
Q4 		$1.94M Buy
13,044
+4,687
+56% +$718K 0.01% 1082
2021
Q3 		$1.22M Sell
8,357
-19,539
-70% -$3.35M 0.01% 1219
2021
Q2 		$5.46M Buy
27,896
+26,609
+2,068% +$4.82M 0.04% 609
2021
Q1 		$233K Sell
1,287
-22,523
-95% -$3.89M ﹤0.01% 1296
2020
Q4 		$3.37M Sell
23,810
-60,088
-72% -$8.72M 0.03% 563
2020
Q3 		$10.5M Buy
83,898
+61,720
+278% +$6.48M 0.09% 253
2020
Q2 		$1.98M Buy
+22,178
New +$1.73M 0.02% 624

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Voloridge Investment Management's TXG Position: Q2 2026 in Review

Voloridge Investment Management sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 497,157 shares — an estimated $10.6M sold.

Voloridge Investment Management first reported a position in TXG in Q2 2020 and held it in 24 quarters. The position peaked at $35.4M in Q2 2022. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Voloridge Investment Management reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 497,157 10x Genomics shares in Q2 2026, an estimated $10.6M.
  • Voloridge Investment Management first reported a position in 10x Genomics in Q2 2020 and held it in 24 quarters.
  • Voloridge Investment Management's 10x Genomics position peaked at $35.4M in Q2 2022.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.